Navigation Links
Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics

PRINCETON, N.J., Nov. 14, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") announced today that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis.  

Utilizing the funding provided with the earlier Phase I grant, Dermalogix established a novel screening paradigm to effectively identify potent therapeutic compounds from its isoprenylcysteine (IPC) technology platform. These screening efforts resulted in the identification of several IPC compounds possessing anti-inflammatory and anti-microbial activity. This Phase II funding will be used to select a lead drug candidate and commence IND-enabling safety/toxicology studies.

"This award is further validation of the potential for IPC compounds in dermatology. We are pleased to be awarded this grant by the NIH and our objective continues to be the development of our technology with the goal of delivering therapeutic agents to treat skin disease," stated Maxwell Stock, President & CEO.

Dermalogix has a successful track record in receiving and executing on NIH funding. Recently, with National Institute of Allergy and Infectious Diseases (NIAID) SBIR funding, Dermalogix announced that an Investigational New Drug (IND) Application to evaluate IPC compound SIG990 in rosacea has been cleared by the FDA. Dr. Eduardo Perez, VP of R&D and Business Development stated, "Building on the experience and momentum provided by SIG990, we believe successful development of our novel class of topical IPC compounds will provide an important additional, and potentially better, therapeutic option for people suffering atopic dermatitis."  

About Signum Dermalogix
Signum Dermalogix is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information please visit:

SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
2. IntelligentMDx Receives FDA Clearance for IMDx C. difficile for Abbott m2000 Assay, Completes Move of Corporate Headquarters to Waltham
3. Numotion Receives 2013 MDA Company of the Year Award
4. EndoShape Receives 510(k) Clearance for Polymer Embolization Device
5. Actinobac Biomed Founder Receives Two Awards For Promising New Drug
6. ARMGO Pharma Receives Research Grant Award from Kennedys Disease Association to Support Advancement of Rycal Compounds
7. Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System
8. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
9. ARRAYit Corporation Receives Purchase Order from ChemBio
10. IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
11. Par Pharmaceuticals Karen OConnor Receives 2013 Cardinal Health Supply Chain Excellence Award
Post Your Comments:
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
(Date:11/24/2015)... -- Sectra (STO: SECT B) announces that ... multi-year agreement to deploy Breast Imaging PACS in ... the Breast Center a future-proof platform capable of expanding with ... announces that Breast Center of Acadiana has entered ... PACS in its two freestanding imaging centers. This investment will ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to ... for dental implants at her Mississauga, ON practice. Dr. Williams has been ... placement of dental implants. , Missing teeth can lead to a variety of ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced that Dr. Christine Milligan, Global ... Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, Republic ...
(Date:11/24/2015)... MA (PRWEB) , ... November 24, 2015 , ... ... announced that the organization will waive paid entry and parking fees at several ... Hingham, and Monument Mountain in Great Barrington in support of REI’s Black Friday ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the United States to support their local poison centers through donations on Tuesday, ... #GivingTuesday: calls it “a day that inspires people to collaborate in improving ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC launched their ... last week and hit their goal of $20,000 in under 10 hours. ... to bring the new PRO Weight Loss Vest to the market. , The PRO Vest ...
Breaking Medicine News(10 mins):